Biotechnology

New Breakthroughs Offer Hope for Patients with Cystic Fibrosis to Breathe Easier

Two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis. The short-term trials found that the drug combinations improved adult patients' lung function over four weeks. But experts said they were optimistic the results will hold up in the larger, longer-term trials already underway. Researchers point to a  triple-drug approach could open up new options to nearly all cystic